Companies › Exelixis
6 active drug programs in 78 registered trials: 42 Phase 2, 23 Phase 1, 10 Phase 3, 3 Phase 4; Oncology, Gastroenterology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cabozantinib (XL184) Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor | KDR, MET | Phase 4 | Medullary Thyroid Cancer; Hepatocellular Carcinoma; Metastatic Prostate Cancer; Renal Cell Carcinoma … | Jan 2027 |
| Zanzalintinib (XL092) Multi-targeted tyrosine kinase inhibitor targeting FGFR, MET, ROS1, and AXL | FGFR1, FGFR2, FGFR3, FGFR4, MET, KIT, PDGFRA | Phase 3 | Non-Clear Cell Renal Cell Carcinoma; Colorectal Cancer; Meningioma; Head and Neck Squamous Cell Carcinoma … | Dec 2026 |
| XB010 | – | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Nov 2026 |
| XL309 (ISM3091) ATM inhibitor | ATM | Phase 1 | Advanced Solid Tumor | Apr 2027 |
| XB628 | – | Phase 1 | Solid Tumor | May 2027 |
| XB371 | – | Phase 1 | Solid Tumors | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03755791 | Cabozantinib (XL184) | Phase 3 | Hepatocellular Carcinoma | Oncology | Nov 2021 |
| NCT04446117 | Cabozantinib (XL184) | Phase 3 | Metastatic Prostate Cancer | Oncology | Apr 2024 |
| NCT04289779 | Cabozantinib (XL184) | Phase 2 | Bladder Cancer | Oncology | Jun 2025 |
| NCT06962332 | Zanzalintinib (XL092) | Phase 1 | Hepatic Impairment | Gastroenterology | Dec 2025 |
| NCT04204850 | Cabozantinib (XL184) | Phase 2 | Hepatocellular Carcinoma | Oncology | Jun 2026 |
| NCT05502315 | Cabozantinib (XL184) | Phase 2 | Castration-resistant Prostate Cancer | Oncology | Nov 2026 |
| NCT06545331 | XB010 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Oncology | Nov 2026 |
| NCT05425004 | Cabozantinib (XL184) | Phase 2 | Meningioma | Oncology | Dec 2026 |
| NCT05263050 | Cabozantinib (XL184) | Phase 2 | Metastatic Renal Cell Carcinoma | Oncology | Dec 2026 |
| NCT04091750 | Cabozantinib (XL184) | Phase 2 | Melanoma | Oncology | Dec 2026 |
| NCT04893785 | Cabozantinib (XL184) | Phase 2 | Lung Neuroendocrine Neoplasm | Oncology | Dec 2026 |
| NCT05182164 | Cabozantinib (XL184) | Phase 2 | Soft Tissue Sarcoma Adult | Oncology | Dec 2026 |
| NCT05678673 | Zanzalintinib (XL092) | Phase 3 | Non-Clear Cell Renal Cell Carcinoma | Oncology | Dec 2026 |
| NCT04413123 | Cabozantinib (XL184) | Phase 2 | Papillary Renal Cell Carcinoma | Oncology | Dec 2026 |
| NCT05168163 | Cabozantinib (XL184) | Phase 2 | Locally Advanced Hepatocellular Carcinoma | Oncology | Dec 2026 |
| NCT06698250 | Zanzalintinib (XL092) | Phase 2 | Hepatocellular Carcinoma | Oncology | Dec 2026 |
| NCT03937219 | Cabozantinib (XL184) | Phase 3 | Renal Cell Carcinoma | Oncology | Jan 2027 |
| NCT04472767 | Cabozantinib (XL184) | Phase 2 | Hepatocellular Carcinoma | Oncology | Jan 2027 |
| NCT05425940 | Zanzalintinib (XL092) | Phase 3 | Colorectal Cancer | Oncology | Jan 2027 |
| NCT05176483 | Zanzalintinib (XL092) | Phase 1 | Renal Cell Carcinoma (RCC) | Oncology | Jan 2027 |
| NCT04551430 | Cabozantinib (XL184) | Phase 2 | Metastatic Soft-tissue Sarcoma | Oncology | Feb 2027 |
| NCT04963283 | Cabozantinib (XL184) | Phase 2 | Colorectal Adenocarcinoma | Oncology | Feb 2027 |
| NCT06835972 | Cabozantinib (XL184) | Phase 1 | Metastatic Renal Cell Carcinoma | Oncology | Feb 2027 |
| NCT04412629 | Cabozantinib (XL184) | Phase 2 | High Grade Neuroendocrine Neoplasms | Oncology | Mar 2027 |
| NCT05559879 | Cabozantinib (XL184) | Phase 1 | Gynecologic Cancer | Oncology | Apr 2027 |
| NCT05932862 | XL309 (ISM3091) | Phase 1 | Advanced Solid Tumor | Oncology | Apr 2027 |
| NCT04322955 | Cabozantinib (XL184) | Phase 2 | Kidney Cancer | Oncology | May 2027 |
| NCT06952010 | Zanzalintinib (XL092) | Phase 1 | Solid Tumor | Oncology | May 2027 |
| NCT03845166 | Zanzalintinib (XL092) | Phase 1 | Neoplasm Malignant | Oncology | May 2027 |
| NCT06952010 | XB628 | Phase 1 | Solid Tumor | Oncology | May 2027 |
| NCT06912087 | Zanzalintinib (XL092) | Phase 1 | Head and Neck Neoplasms | Oncology | Jun 2027 |
| NCT01639508 | Cabozantinib (XL184) | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Jul 2027 |
| NCT03690388 | Cabozantinib (XL184) | Phase 3 | Differentiated Thyroid Cancer | Oncology | Jul 2027 |
| NCT04200443 | Cabozantinib (XL184) | Phase 2 | Metastatic Leiomyosarcoma | Oncology | Aug 2027 |
| NCT03635892 | Cabozantinib (XL184) | Phase 2 | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Oncology | Aug 2027 |
| NCT05048901 | Cabozantinib (XL184) | Phase 1 | Neuroendocrine Tumors,Gastroenteropancreatic | Gastroenterology | Aug 2027 |
| NCT05931393 | Cabozantinib (XL184) | Phase 2 | RCC | Oncology | Sep 2027 |
| NCT07077161 | Cabozantinib (XL184) | Phase 2 | Renal Cell Carcinoma (RCC) | Oncology | Sep 2027 |
| NCT03170960 | Cabozantinib (XL184) | Phase 1 | Urothelial Carcinoma | Oncology | Sep 2027 |
| NCT05361720 | Cabozantinib (XL184) | Phase 2 | Advanced Clear Cell Renal Cell Carcinoma | Oncology | Oct 2027 |
| NCT04116541 | Cabozantinib (XL184) | Phase 2 | Malignant Solid Tumor | Oncology | Oct 2027 |
| NCT06156410 | Cabozantinib (XL184) | Phase 1 | Ewing Sarcoma | Oncology | Nov 2027 |
| NCT06132945 | Cabozantinib (XL184) | Phase 1 | Metastatic Renal Cell Carcinoma | Oncology | Nov 2027 |
| NCT07123103 | XB371 | Phase 1 | Solid Tumors | Oncology | Nov 2027 |
| NCT05127824 | Cabozantinib (XL184) | Phase 2 | Carcinoma, Renal Cell | Oncology | Dec 2027 |
| NCT05249114 | Cabozantinib (XL184) | Phase 1 | Neuroendocrine Tumors | Oncology | Dec 2027 |
| NCT04588051 | Cabozantinib (XL184) | Phase 2 | HCC | Oncology | Dec 2027 |
| NCT07428616 | Zanzalintinib (XL092) | Phase 2 | Meningioma | Oncology | Feb 2028 |
| NCT06959511 | Zanzalintinib (XL092) | Phase 2 | Neoadjuvant Treatment | Oncology | Mar 2028 |
| NCT06934057 | Cabozantinib (XL184) | Phase 4 | Kidney Cancer | Oncology | Apr 2028 |
| NCT05836571 | Cabozantinib (XL184) | Phase 2 | Locally Advanced Extraskeletal Myxoid Chondrosarcoma | Oncology | May 2028 |
| NCT06794229 | Zanzalintinib (XL092) | Phase 2 | Locally Advanced Renal Cell Carcinoma | Oncology | Jun 2028 |
| NCT05327686 | Cabozantinib (XL184) | Phase 2 | Metastatic Renal Cell Carcinoma | Oncology | Jun 2028 |
| NCT03539822 | Cabozantinib (XL184) | Phase 1 | Gastric Cancer | Oncology | Jun 2028 |
| NCT06571734 | Zanzalintinib (XL092) | Phase 2 | Metastatic Leiomyosarcoma | Oncology | Jul 2028 |
| NCT07218666 | Zanzalintinib (XL092) | Phase 2 | Aggressive Variant Prostate Carcinoma | Oncology | Jul 2028 |
| NCT06082167 | Zanzalintinib (XL092) | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Aug 2028 |
| NCT06959641 | Zanzalintinib (XL092) | Phase 2 | Locally Advanced Differentiated Thyroid Gland Carcinoma | Oncology | Sep 2028 |
| NCT05613413 | Cabozantinib (XL184) | Phase 2 | Metastatic Squamous Non-Small Cell Lung Carcinoma | Oncology | Sep 2028 |
| NCT07028125 | Cabozantinib (XL184) | Phase 4 | Renal Cell Carcinoma (Kidney Cancer) | Oncology | Oct 2028 |
The 60 nearest readouts of 78 trials; the rest in the app.
Cash and short-term investments of $892m on 2026-10-02; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Genmab Immunocore Hutchmed Nurix Therapeutics Jazz Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.